You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

mass. mover

Biogen Idec slips after stock’s rating is cut

Weston-based Biogen Idec makes  drugs to treat neurodegenerative diseases, hemophilia, and autoimmune disorders.

Suzanne Kreiter/Globe Staff

Weston-based Biogen Idec makes drugs to treat neurodegenerative diseases, hemophilia, and autoimmune disorders.

Continue reading below

Biogen Idec Inc., maker of the multiple sclerosis drug Tecfidera, fell after Citigroup cut the stock to “neutral” from “buy.” The shares had rallied 52 percent this year through Tuesday, Bloomberg News reported. Citi’s analyst cited concerns about regulatory protections for Tecfidera in the European Union when other drug makers submit applications to make generic versions.

Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.